SCHEMBL755739

SCHEMBL755739

O=C(c1ccc(Cc2ccc(F)cc2)o1)c1oc(C=NO)cc(=O)c1OCc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 1/20 0.38
MAPT P10636 7/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
POLB P06746 4/20 0.35
L3MBTL1 Q9Y468 4/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MAOA P21397 1/20 0.35
KMT2A Q03164 4/20 0.35
MEN1 O00255 3/20 0.35
TDP1 Q9NUW8 1/20 0.34
TSHR P16473 1/20 0.34
LMNA P02545 1/20 0.33
NR4A2 P43354 1/20 0.33
MAOB P27338 1/20 0.33
NPC1 O15118 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16921615 1.00 PTGER1 (0.38) PTGER1MAPTGAAHPGDSMN1; SMN2
SCHEMBL753158 0.91 PTGER1 (0.40) PTGER1MAPTSMN1; SMN2POLBL3MBTL1
SCHEMBL16921611 0.90 MAPT (0.36) PTGER1MAPTHPGDSMN1; SMN2POLB
SCHEMBL754394 0.90 MAPT (0.36) PTGER1MAPTHPGDSMN1; SMN2POLB
SCHEMBL16921613 0.87 SMN1; SMN2 (0.36) PTGER1MAPTHPGDSMN1; SMN2ALDH1A1
SCHEMBL16925516 0.85 FAAH (0.33) SMN1; SMN2POLBALDH1A1KMT2AMEN1
SCHEMBL752918 0.85 MAPT (0.43) PTGER1MAPTSMN1; SMN2POLBL3MBTL1
SCHEMBL751907 0.84 PTGER1 (0.40) PTGER1MAPTGAASMN1; SMN2POLB
SCHEMBL16921603 0.84 SMN1; SMN2 (0.43) PTGER1MAPTGAASMN1; SMN2POLB
SCHEMBL16921609 0.83 LOXL2 (0.44) PTGER1MAPTSMN1; SMN2POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2266958-B1 Antiviral agent SHIONOGI & CO (JP) 2017-03-15 EP disclosed
US-20170066754-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2017-03-09 US disclosed
US-9572813-B2 Antiviral agent SHIONOGI & CO., LTD. (JP) 2017-02-21 US disclosed
EP-3042894-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2016-07-13 EP disclosed
US-20150202208-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2015-07-23 US disclosed
EP-1422218-B1 ANTIVIRAL AGENT SHIONOGI & CO (JP) 2012-03-21 EP disclosed
EP-2181985-B1 Antiviral Agent SHIONOGI & CO (JP) 2011-10-26 EP disclosed
EP-2266958-A1 Antiviral agent SHIONOGI & CO., LTD. (JP) 2010-12-29 EP disclosed
EP-2181985-A1 Antiviral Agent SHIONOGI & CO., LTD. (JP) 2010-05-05 EP disclosed
US-20040229909-A1 Antiviral agent SHIONOGI & CO., LTD. (JP) 2004-11-18 US disclosed
EP-1422218-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2004-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229909-A1 Antiviral agent ZC3HAV1, ZC3HAV1L, DUT PTGER1 4133/4885MAPT 4635/4885GAA 1106/4885
US-20150202208-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI PTGER1 3786/4885MAPT 4426/4885GAA 1442/4885
US-20170066754-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI PTGER1 3786/4885MAPT 4426/4885GAA 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.